Sermorelin Global Regulatory Status: FDA History, Label Requirements, and Safety Record
Key numbers
- 0.05 mgGeref approved dose for the 1990 diagnostic test of pituitary growth hormone releaseSource: federalregister.gov, as cited Nov 7, 2026
- 0.5 mg and 1 mgApproved vial strengths for idiopathic growth hormone deficiency in children with growth failureSource: federalregister.gov, as cited Nov 7, 2026
- 30 micrograms/kgStudied pediatric dose, not a recommended dose, given once daily at bedtimeSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 8.0 cm/yrMean height velocity at 6 months on the studied pediatric dose, up from 4.1 cm/yr at baselineSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Sermorelin
At a glance
- FDA approvals / 0.05 mg on Dec 28, 1990; 0.5 mg and 1 mg vials on Sept 26, 1997 [1]
- Approved uses / Pituitary growth hormone reserve test; pediatric growth hormone deficiency [1]
- Withdrawal / Maker stopped Geref in 2008; approvals withdrawn June 18, 2009 [1]
- 2013 FDA finding / Not withdrawn for safety or effectiveness reasons [1][2]
- Current US status / Compounded only; no approved product [3]
- Sport / WADA S2.2.4, prohibited at all times [4]
What sermorelin is
Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH), the shortest synthetic peptide with the full biological activity of GHRH [5]. It is not growth hormone; it prompts the pituitary to release the body's own growth hormone [5].
The two FDA approvals, and the withdrawal
Geref 0.05 mg per ampule, NDA 019863, was approved on December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone [1]. Geref 0.5 mg and 1 mg per vial, NDA 020443, was approved on September 26, 1997 for idiopathic growth hormone deficiency in children with growth failure [1]. Neither covered adults, anti-aging, weight loss or athletic performance, and these two are the only sermorelin applications in Drugs@FDA [1][2].
The maker notified FDA of discontinuation in July and December 2008 and asked FDA to withdraw the applications [1]. FDA withdrew both effective June 18, 2009 [1]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [1][2].
Dr Alex Tatem on how sermorelin stayed legal after its FDA withdrawal
Dr Alex Tatem argues that sermorelin's place on the market rests on a regulatory accident rather than a safety problem. He says the drug was approved as Geref, lost out to recombinant growth hormone in the marketplace, and was never pulled for harm. In his view, one citizen petition and one written FDA answer, stating Geref was not withdrawn for safety or effectiveness reasons, is why compounded sermorelin can still be sold. He also says the strongest evidence is for sleep, while claims about muscle and longevity are weakly supported, and he urges viewers to be realistic about what it can do.
Who is speaking?
Dr. Alex Tatem. Physician and host, as described on the channel Dr. Alex Tatem Background
What is available in the US now
With Geref off the market, sermorelin sold in the US is compounded, not FDA-approved; FDA does not review the safety, effectiveness or quality of compounded drugs before they are marketed [3]. Sermorelin is not on FDA's list of bulk substances that may present significant safety risks when compounded [6]. On FDA's nominated bulk substances list for outsourcing facilities, updated March 21, 2025, sermorelin acetate is in category 1, under evaluation [7]. It appears in no category on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026 [8].
HealthRX.com offers sermorelin by prescription as a compounded product.
Is there a sermorelin label today?
No. Both applications are withdrawn, so no sermorelin product holds FDA approval and there is no current approved dose [1]. The doses on record are the ones studied, and they are not recommended doses: 30 micrograms/kg once daily subcutaneously at bedtime in the pediatric program, and 0.5 mg or 1 mg twice daily for 14 days in a short physiology study of older men [9][10].
What the safety record shows
A 1-year, open-label, multicenter study enrolled 110 previously untreated prepubertal children with growth hormone deficiency, 86 evaluable, on 30 micrograms/kg subcutaneously at bedtime [9]. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months [9]. Seventy-four percent were good responders at 6 months [9]. No adverse changes appeared in general biochemical or hormonal analyses, fasting glucose did not change, IGF-I was not excessively raised, and the drug was well tolerated overall [9].
Questions worth asking
Sport
WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, prohibited at all times, in and out of competition [4]. It is named in the 2027 List as well, in force January 1, 2027 [11].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
When was sermorelin FDA approved?
Is sermorelin still FDA-approved?
What does the safety record show?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is sermorelin legal in the United States?
No. Sermorelin is not FDA-approved in the United States today. Sermorelin sold here is compounded, and FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. The approved version, Geref, was withdrawn effective June 18, 2009, after its maker discontinued it in 2008.
Is sermorelin banned in bodybuilding?
Yes, in sport. WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, which is prohibited at all times, in and out of competition. It is named in the 2027 List as well, in force January 1, 2027.
References
Show all 12 referencesHide references
- Federal Register :: Request Access.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- World Anti-Doping Agency.
- Dr. Alex Tatem. Sermorelin: The "Safer HGH" Has One Huge Problem. Accessed 2026-11-11.